https://www.selleckchem.com/pr....oducts/wortmannin.ht
OBJECTIVES To identify and characterise a subgroup of patients with early rheumatoid arthritis (RA) reporting not feeling well 1 year after treatment initiation despite achieving optimal disease control according to current treatment standards. METHODS This observational study included participants of the Care in early RA trial with a rapid and sustained response (DAS28CRP less then 2.6) from week 16 until year 1 after starting the first RA treatment. Feeling well was assessed at year 1, using five patient-reported outcomes (PROs) pa